| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 211 | 2018 |
| Antiretroviral adherence level necessary for HIV viral suppression using real-world data KK Byrd, JG Hou, R Hazen, H Kirkham, S Suzuki, PG Clay, T Bush, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 82 (3), 245-251, 2019 | 198 | 2019 |
| The abacavir hypersensitivity reaction: a review PG Clay Clinical therapeutics 24 (10), 1502-1514, 2002 | 178 | 2002 |
| Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens PG Clay, S Nag, CM Graham, S Narayanan Medicine 94 (42), e1677, 2015 | 144 | 2015 |
| Complementary and alternative medicine use among Hispanics in the United States BI Ortiz, KM Shields, KA Clauson, PG Clay Annals of Pharmacotherapy 41 (6), 994-1004, 2007 | 106 | 2007 |
| The essential research curriculum for doctor of pharmacy degree programs MW Lee, PG Clay, WK Kennedy, MJ Kennedy, NM Sifontis, D Simonson, ... Pharmacotherapy 30 (9), 966, 2010 | 59 | 2010 |
| Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 … PG Clay, MR Graham, CC Lindsey, KC Lamp, C Freeman, A Glaros The American journal of geriatric pharmacotherapy 2 (3), 181-189, 2004 | 52 | 2004 |
| Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study RD MacArthur, TN Hawkins, SJ Brown, A LaMarca, PG Clay, AC Barrett, ... HIV clinical trials 14 (6), 261-273, 2013 | 50 | 2013 |
| A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV PG Clay, WC Yuet, CH Moecklinghoff, I Duchesne, KL Tronczyński, ... AIDS Research and Therapy 15, 1-10, 2018 | 49 | 2018 |
| Noninfectious diarrhea in HIV seropositive individuals: a review of prevalence rates, etiology, and management in the era of combination antiretroviral therapy PG Clay, RD Crutchley Infectious diseases and therapy 3, 103-122, 2014 | 44 | 2014 |
| Management protocol for abacavir-related hypersensitivity reaction PG Clay, RC Rathbun, LN Slater Annals of Pharmacotherapy 34 (2), 247-249, 2000 | 41 | 2000 |
| PaCIR: A tool to enhance pharmacist patient care intervention reporting PG Clay, AL Burns, BJ Isetts, JD Hirsch, MA Kliethermes, LG Planas Journal of the American Pharmacists Association 59 (5), 615-623, 2019 | 36 | 2019 |
| Adherence and viral suppression among participants of the patient-centered human immunodeficiency virus (HIV) care model project: a collaboration between community-based … KK Byrd, JG Hou, T Bush, R Hazen, H Kirkham, A Delpino, PJ Weidle, ... Clinical infectious diseases 70 (5), 789-797, 2020 | 35 | 2020 |
| Pseudo-Parkinson disease secondary to ritonavir–buspirone interaction PG Clay, MM Adams Annals of Pharmacotherapy 37 (2), 202-205, 2003 | 33 | 2003 |
| Valid treatment options for osteoporosis and osteopenia in HIV-infected persons PG Clay, LE Voss, C Williams, EC Daume Annals of Pharmacotherapy 42 (5), 670-679, 2008 | 30 | 2008 |
| Poly-L-lactic acid for facial lipoatrophy in HIV C El-Beyrouty, V Huang, CJ Darnold, PG Clay Annals of Pharmacotherapy 40 (9), 1602-1606, 2006 | 27 | 2006 |
| Retention in HIV care among participants in the patient-centered HIV care model: a collaboration between community-based pharmacists and primary medical providers KK Byrd, F Hardnett, PG Clay, A Delpino, R Hazen, MD Shankle, ... AIDS patient care and STDs 33 (2), 58-66, 2019 | 25 | 2019 |
| Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects C Hicks, P Clay, R Redfield, J Lalezari, R Liporace, S Schneider, ... AIDS research and human retroviruses 29 (2), 250-255, 2013 | 24 | 2013 |
| Costs to physician offices of providing medications to medically indigent patients via pharmaceutical manufacturer prescription assistance programs P Clay, E Vaught, A Glaros, S Mangum, D Hansen, CC Lindsey Journal of Managed Care Pharmacy 13 (6), 506-514, 2007 | 23 | 2007 |
| Patient-Centered HIV Care Model Team. Antiretroviral adherence level necessary for HIV viral suppression using realworld data KK Byrd, JG Hou, R Hazen, H Kirkham, S Suzuki, PG Clay J Acquir Immune Defic Syndr 82 (3), 245-251, 2019 | 21 | 2019 |
